Beaulieu International Group and Digimarc Demonstrate Digital Watermarks as a Scalable Solution for Digital Product Passports in the Flooring Industry
5.8.2025 17:00:00 CEST | Business Wire | Press Release
Beaulieu International Group (B.I.G.), a global leader in material and flooring solutions, and Digimarc Corporation (NASDAQ: DMRC), a pioneer in digital watermarking technologies, have successfully demonstrated that invisible digital watermarks are a highly effective solution for delivering CPR-mandated construction Digital Product Passports (DPP) to the flooring industry while uniquely meeting its complex needs.
“Facilitating the circular economy through DPP compliance is a top priority for Beaulieu, because eventually, all flooring products will be removed and replaced,” said Nele Cattoor, B.I.G.’s Regulatory Compliance Lead. “The challenge was to find a data carrier that not only functions while the flooring is in place, but also survives the damage that inevitably occurs during removal. This data carrier must therefore be imperceptible to the human eye—something that could be integrated directly onto the surface of our flooring solutions—without affecting the design, appearance, or thickness. It must also be pervasive and durable enough to remain detectable even on small, cut, or damaged pieces of material.”
Traditional technologies, such as QR codes, NFC, and RFID cannot meet these requirements. “You could potentially be technically DPP-compliant by printing QR codes on the backs of glue-down flooring, but once the flooring is installed, those codes can no longer be read, nor are they likely to survive the removal process and therefore be accessible to recycling facilities,” explained Dorine Degryse, Sustainability Coordinator CV at B.I.G. “As a company committed to sustainable living, that was not acceptable. We needed something better—and we found it in Digimarc’s digital watermarking technology.”
Digimarc’s invisible, thumbnail-sized digital watermarks cover the entire surface of the product in a redundant pattern, making them robust, long-lasting, and detectable even after substantial wear and tear. Each watermark carries a unique digital ID linked to product-specific data hosted on Digimarc’s Illuminate SaaS platform, enabling a seamless DPP experience via mobile or web applications. Requiring no special ink or printing process, the solution is highly scalable and cost-effective compared to many traditional alternatives. Most importantly, due to their covert nature and robustness, Digimarc digital watermarks can support the entire life cycle of flooring, from installation all the way to recycling.
B.I.G. partnered with Digimarc to validate the technology’s performance in real-world flooring scenarios. Together, the teams enhanced six B.I.G. artworks with digital watermarks, created corresponding DPP profiles within Digimarc’s beta DPP module, and successfully scanned the products to simulate field use.
The success of this initiative was showcased at major industry events, including Flanders Flooring Days in June 2025 and the VinylPlus® Digital Product Passport event in Brussels in January 2025. Both demonstrations generated significant interest from flooring manufacturers facing similar DPP compliance challenges. “Many attendees had never encountered digital watermarking before, so seeing our solution in action—providing instant, invisible access to critical sustainability, circularity, and compliance information stored in the cloud—was eye-opening,” said Lara Misseeuw, Innovation Project Manager at B.I.G. “It quickly became clear to the industry why digital watermarking technology is so valuable as a next-generation data carrier, which we can use as a more durable and sustainable option alongside, for example, QR codes printed on the backs of products, if desired.”
Digimarc has also presented this successful collaboration to the technical group responsible for standards harmonization for the flooring industry (CEN/TC 134 WG 10, AHG Tagging). “Our ambition is to establish digital watermarks as the industry-validated data carrier for construction materials, starting with flooring,” said Riley McCormack, President and CEO at Digimarc. “Digital watermarks are a natural fit for construction products because of their invisibility, resilience, redundancy, and simple detection using a mobile phone or scanner. And because they can be applied using varnishes, etchings, molds, and inks, the technology is compatible with a wide range of materials, including pipes, panels, and tiles.”
“Our next step is to continue collaborating with the VinylPlus consortium to drive momentum for digital watermarks as the data carrier of choice to deliver CPR-mandated construction Digital Product Passports (DPP) for the flooring industry,” concluded McCormack.
Learn more about Digimarc’s digital watermarks.
About Beaulieu International Group (B.I.G.)
As a global family business, we develop and co-create—in an innovative, entrepreneurial and sustainable way—flooring and material solutions to enhance the quality of living and working for every generation. Headquartered in Belgium, B.I.G. employs over 4,500 people worldwide in 19 countries throughout Eurasia, America, and Oceania and serves customers in 150 countries. In 2024, B.I.G. reported sales of €2 billion. At B.I.G., we work purposefully to build a sustainable future. Our sense of entrepreneurship and our ambition enable us to continue to grow together with our employees, customers, suppliers, shareholders, and the society in which we operate.
About Digimarc
Digimarc Corporation (NASDAQ: DMRC) is the pioneer and global leader in digital watermarking technologies for the identification and authentication of physical and digital items. For nearly 30 years, Digimarc innovations and intellectual property in digital watermarking have been deployed at a massive scale and across a wide range of industries. A notable example is our partnership with a consortium of the world’s central banks to deter counterfeiting of global currency. Digimarc is also instrumental in supporting global industry standards efforts spanning both the physical and digital worlds. In 2023, Digimarc was named to the Fortune 2023 Change the World list and honored as a 2023 Fast Company World Changing Ideas finalist. Learn more at Digimarc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250805143891/en/
Contacts
Media Contacts:
Digimarc Corporation
Mike Fitzsimons
PR@digimarc.com
503-469-4800
Beaulieu International Group
Sara Geris, Corporate Communications Director
sara.geris@bintg.com
+32496705879
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom